News and Announcements
Rapid Response Revival makes significant Board appointment and signs a mandate with a US Investment Bank as Lead Manager for the planned IPO in October
- Published January 11, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Rapid Response Revival Research Limited has appointed Greg Bodkin, a member of Cochlear’s senior executive team, as a Non-Executive Director to the Board.
Greg Bodkin has functional responsibility within Cochlear for new product industrialisation, procurement, manufacturing and logistics, enabling the technologies in design and development to be supplied as commercial products into global markets.
Greg brings to the board 30 years of experience in Operations and Supply Chain Management in Class 3 Medical Devices and his working knowledge and experience of how to implement, grow and manage a complex global supply chain that supports supply of a medical device will be hugely valuable to RRR.
Know more about Greg Bodkin’s bio on the Cochlear corporate webpage via this link.
With an eye towards the IPO planned for October this year, Rapid Response Revival Research Limited has executed a mandate with a US Investment Bank to be a lead manager and underwriter to the issue. This mandate includes working with RRR to provide leadership in any private capital raising rounds, as required in the lead up to the IPO.
The IB is ranked No.1 in Healthcare Investment Banking in the US, and has completed over 200 transactions in companies in the Medical Device, Diagnostic Tools, and Life Sciences sectors over the last 2 years.
About Rapid Response Revival Research Limited
Rapid Response Revival are the innovators behind the CellAED® defibrillator technology – transforming everyday people into heroes.
Sudden Cardiac Arrest (SCA) has an extremely high death rate and is a leading cause of death globally, accounting for more deaths than many cancers, influenza, car accidents and house fire deaths combined. Anyone can suffer from SCA, regardless of age, gender or fitness level – including children. The current survival rate is just 2-11%.
The CellAED® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
